Research ArticleOriginal Article
Open Access

Valproic acid for children below 2 years of age with epilepsy

Osama Y. Muthaffar, Salha M. Almahmudi, Muna O. Alrabghi, Maria M. Bin Mahfouz and Nuha S. Alfawaz
Neurosciences Journal October 2021, 26 (4) 357-365; DOI: https://doi.org/10.17712/nsj.2021.4.20210075

References

  1. 1.↵
    1. Hunter MB,
    2. Yoong M,
    3. Sumpter RE,
    4. Verity K,
    5. Shetty J,
    6. McLellan A, et al.
    Incidence of early-onset epilepsy: A prospective population-based study. Seizure 2020; 75: 49–54.
    OpenUrl
  2. 2.↵
    1. Bombardieri R,
    2. Pinci M,
    3. Moavero R,
    4. Cerminara C,
    5. Curatolo P.
    Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol 2010; 14: 146–149.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Sahu PK,
    2. Mishra D,
    3. Juneja M,
    4. Taneja K.
    Clinico-etiological Profile and Developmental Status of Infants Aged 1-24 months with Epilepsy. Indian J Pediatr 2019; 86: 681–685.
    OpenUrl
  4. 4.↵
    1. Eltze CM,
    2. Chong WK,
    3. Cox T,
    4. Whitney A,
    5. Cortina-Borja M,
    6. Chin RF, et al.
    A population-based study of newly diagnosed epilepsy in infants. Epilepsia 2013; 54: 437–445.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Kwon SH,
    2. Scheinost D,
    3. Lacadie C,
    4. Benjamin J,
    5. Myers EH,
    6. Qiu M, et al.
    GABA, resting-state connectivity and the developing brain. Neonatology 2014; 106: 149–155.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Tomson T,
    2. Battino D,
    3. Perucca E.
    Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol 2016; 15: 210–218.
    OpenUrl
  7. 7.↵
    1. Bryant AE 3rd.,
    2. Dreifuss FE.
    Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465–469.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Wang Y,
    2. Hu W,
    3. Li Z.
    Influence of age and co-medication on the concentration and efficacy of valproic acid in Chinese epilepsy children. Pak J Pharm Sci 2020; 33: 537–542.
    OpenUrl
  9. 9.↵
    1. Koenig SA,
    2. Buesing D,
    3. Longin E,
    4. Oehring R,
    5. Häussermann P,
    6. Kluger G, et al.
    Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006; 47: 2027–2031.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Ghodke-Puranik Y,
    2. Thorn CF,
    3. Lamba JK,
    4. Leeder JS,
    5. Song W,
    6. Birnbaum AK, et al.
    Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2013; 23: 236–241.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Zhu MM,
    2. Li HL,
    3. Shi LH,
    4. Chen XP,
    5. Luo J,
    6. Zhang ZL.
    The pharmacogenomics of valproic acid. J Hum Genet 2017; 62: 1009–1014.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Guo HL,
    2. Jing X,
    3. Sun JY,
    4. Hu YH,
    5. Xu ZJ,
    6. Ni MM, et al.
    Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. Curr Pharm Des 2019; 25: 343–351.
    OpenUrlCrossRef
  13. 13.↵
    1. Meseguer ES,
    2. Elizalde MU,
    3. Borobia AM,
    4. Ramírez E.
    Valproic Acid-Induced Liver Injury: A Case-Control Study from a Prospective Pharmacovigilance Program in a Tertiary Hospital. J Clin Med 2021; 10: 1153.
    OpenUrl
  14. 14.↵
    1. Cofini M,
    2. Quadrozzi F,
    3. Favoriti P,
    4. Favoriti M,
    5. Cofini G.
    Valproic acid-induced acute pancreatitis in pediatric age: case series and review of literature. G Chir 2015; 36: 158–160.
    OpenUrl
  15. 15.↵
    1. Rosati A,
    2. Ilvento L,
    3. Lucenteforte E,
    4. Pugi A,
    5. Crescioli G,
    6. McGreevy KS, et al.
    Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. Epilepsia 2018; 59: 297–314.
    OpenUrl
  16. 16.
    1. Yang X,
    2. Wang P,
    3. Pan J,
    4. Wang C,
    5. Luo J,
    6. Ma H.
    Valproic acid concentration and biochemical indexes in epilepsy outpatients during monotherapy or combination therapy. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2020; 45: 782–789.
    OpenUrl
  17. 17.
    1. Du Y,
    2. Lin J,
    3. Shen J,
    4. Ding S,
    5. Ye M,
    6. Wang L, et al.
    Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015. BMC Pharmacol Toxicol 2019; 20: 7.
    OpenUrl
  18. 18.↵
    1. Wilmshurst JM,
    2. Gaillard WD,
    3. Vinayan KP,
    4. Tsuchida TN,
    5. Plouin P,
    6. Van Bogaert P,
    7. Carrizosa J,
    8. Elia M,
    9. Craiu D,
    10. Jovic NJ,
    11. Nordli D,
    12. Hirtz D,
    13. Wong V,
    14. Glauser T,
    15. Mizrahi EM,
    16. Cross JH.
    Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia 2015; 56: 1185–1197.
    OpenUrl
  19. 19.↵
    1. Ee LC,
    2. Shepherd RW,
    3. Cleghorn GJ,
    4. Lewindon PJ,
    5. Fawcett J,
    6. Strong RW,
    7. Lynch SV.
    Acute liver failure in children: A regional experience. J Paediatr Child Health 2003; 39: 107–110.
    OpenUrlCrossRefPubMed
  20. 20.
    1. Hussein RS,
    2. Soliman RH,
    3. Abdelhaleem A,
    4. Tawfeik MH,
    5. Abdelrahim M.
    Effect of antiepileptic drugs on liver enzymes. Beni-Suef University Journal of Basic and Applied Sciences 2013: 2: 14–19.
    OpenUrl
  21. 21.↵
    1. Adedapo ADA,
    2. Demaki WE,
    3. Lagunju I.
    Non-Dose-Dependent Changes in Liver Enzyme Levels of Children With Epilepsy on Treatment With Sodium Valproate. Dose Response 2020; 18: 1559325820918445.
    OpenUrl
  22. 22.↵
    1. Aithal GP,
    2. Watkins PB,
    3. Andrade RJ,
    4. Larrey D,
    5. Molokhia M,
    6. Takikawa H,
    7. Hunt CM,
    8. Wilke RA,
    9. Avigan M,
    10. Kaplowitz N,
    11. Bjornsson E,
    12. Daly AK.
    Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806–815.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Yu YC,
    2. Mao YM,
    3. Chen CW,
    4. Chen JJ,
    5. Chen J,
    6. Cong WM, et al.
    Drug-induced Liver Injury (DILI) Study Group; Chinese Society of Hepatology (CSH); Chinese Medical Association (CMA). CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017; 11: 221–241.
    OpenUrl
  24. 24.↵
    1. Chicharro AV,
    2. de Marinis AJ,
    3. Kanner AM.
    The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist? Epilepsy Behav 2007; 11: 361–366.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Gayam V,
    2. Mandal AK,
    3. Khalid M,
    4. Shrestha B,
    5. Garlapati P,
    6. Khalid M.
    Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review. J Community Hosp Intern Med Perspect. 2018; 8: 311–314.
    OpenUrl
  26. 26.↵
    1. Kriel RL,
    2. Fischer JH,
    3. Cloyd JC,
    4. Green KH,
    5. Fraser GL.
    Valproic acid pharmacokinetics in children: III. Very high dosage requirements. Pediatr Neurol 1986; 2: 202–208.
    OpenUrlPubMed
  27. 27.↵
    1. Ghozzi H,
    2. Hakim A,
    3. Sahnoun Z,
    4. Ben Mahmoud L,
    5. Atheymen R,
    6. Hammami S,
    7. Zeghal K.
    [Relationship between plasma concentrations of valproic acid and hepatotoxicity in patients receiving high doses]. Rev Neurol (Paris) 2011; 167: 600–606.
    OpenUrlPubMed
  28. 28.↵
    1. Serragui S,
    2. Zalagh F,
    3. Tanani DS,
    4. Ouammi L,
    5. Moussa LA,
    6. Badrane N, et al.
    [Therapeutic drug monitoring of three antiepileptic drugs - Back on twenty years of experience]. Pan Afr Med J 2016; 25: 10.
    OpenUrlPubMed
  29. 29.↵
    1. Wahba A,
    2. Bergez E.
    Severe Pancytopenia Induced by Valproic Acid. Cureus 2020; 12: e11252.
    OpenUrl
  30. 30.↵
    1. Sirven JI,
    2. Noe K,
    3. Hoerth M,
    4. Drazkowski J.
    Antiepileptic drugs 2012: recent advances and trends. Mayo Clin Proc 2012; 87: 879–889.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Nanau RM,
    2. Neuman MG.
    Adverse drug reactions induced by valproic acid. Clin Biochem 2013; 46: 1323–1338.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Koenig SA,
    2. Buesing D,
    3. Longin E,
    4. Oehring R,
    5. Häussermann P,
    6. Kluger G, et al.
    Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006; 47: 2027–2031.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Star K,
    2. Edwards IR,
    3. Choonara I.
    Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase. PLoS One 2014; 9: e108970.
    OpenUrlCrossRefPubMed
  34. 34.
    1. Auvichayapat N,
    2. Tassniyom S,
    3. Treerotphon S,
    4. Auvichayapat P.
    Treatment of infantile spasms with sodium valproate followed by benzodiazepines. J Med Assoc Thai 2007; 90: 1809–1814.
    OpenUrlPubMed
  35. 35.
    1. Siemes H,
    2. Spohr HL,
    3. Michael T,
    4. Nau H.
    Therapy of infantile spasms with valproate: results of a prospective study. Epilepsia 1988; 29: 553–560.
    OpenUrlPubMedWeb of Science
  36. 36.↵
    1. Wilmshurst JM,
    2. Burman R,
    3. Gaillard WD,
    4. Cross JH.
    Treatment of infants with epilepsy: Common practices around the world. Epilepsia 2015; 56: 1033–1046.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section